Karen Pendergrass

Karen Pendergrass, Standards Team

About

Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.

Recent Posts

2026-07-05

Alterations in the human oral and gut microbiomes and lipidomics in COVID-19

COVID-19 patients showed reduced oral and gut microbial diversity, with fewer butyric-acid-producing and more lipopolysaccharide-producing bacteria. Classifiers built on 8 oral and 7 fecal microbial markers diagnosed COVID-19 with area-under-curve values above 0.87, and diagnosed antibody-positive suspected cases.

2026-07-05

The gut microbiota-SCFA-inflammation axis in patients with AECOPD

In 24 patients with acute exacerbation of COPD versus 18 healthy controls, gut microbiota richness and diversity fell, short-chain fatty acids dropped across all six measured acids, and serum IL-6 was reduced, supporting a gut microbiota-SCFA-inflammation axis.

2026-07-05

Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease

Parkinson's patients had a distinct, potentially pro-inflammatory microbiota in the deep nasal sinus cavity near the olfactory bulb. Moraxella catarrhalis was enriched in patients and correlated with more severe motor scores, while short-chain-fatty-acid-producing bacteria were reduced.